1 published article · Updated continuously
17 trials tracked for Cutaneous T-cell Lymphoma: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 654 citations.
Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Brentuximab Vedotin demonstrated significant clinical efficacy in patients with Cutaneous T-cell Lymphoma, achieving a 54.7% rate of Objective Response lasting at least 4 months (ORR4) compared to 12.5% in the control group (p<0.001). Furthermore, it showed superior rates for Complete Response (CR) (17.2% vs. 1.6%, p=0.0002) and Progression-Free Survival (PFS) (16.7% vs. 3.5%, p<0.001) 2.
SGX301 (synthetic hypericin) showed significant improvement in skin lesions compared to placebo. Specifically, the number of responders was significantly higher in the SGX301 group than in the placebo group across multiple assessment points, including a 50% improvement in CAILS scores 3.
Romidepsin is established as an intervention for this condition; however, its administration is associated with a significantly higher rate and severity of adverse events compared to other cohorts (p<0.01) 15. Phase 1 data also confirmed the use of Romidepsin, reporting specific progression-free survival and duration of response metrics 17.
KW-0761 was evaluated in both large-scale Phase 3 trials and smaller Phase 2 studies, with results indicating impacts on Quality of Life (QoL) as measured by the Skindex-29 Symptoms Scale [1, 11].
AI synthesis of 8 cited trials, updated Jul 3, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
